Prescient Therapeutics, a cancer treatment developer listed on the ASX with a market capitalisation of $72 million, has initiated an $8 million capital raising targeted at existing investors to advance its clinical trials. The company, which specialises in developing next-generation cancer therapies that harness a patient's immune system, is working on innovative treatments that could significantly impact cancer care. Boutique advisory firm Reach Markets is facilitating the share purchase plan for the fundraising effort. The company's CEO, Steven Yatomi-Clarke, has been actively investing in the development of these immune-based therapies, which represent a cutting-edge approach in oncology. The capital raise is part of Prescient's strategy to accelerate the progression of its clinical trials, which are critical for obtaining regulatory approvals and bringing new treatments to market. This funding round follows previous developments in the company's pipeline, including a notable article published on August 17, 2020, which highlighted the company's focus on immune system-based cancer therapies. The company's recent activities underscore its commitment to advancing innovative cancer treatments, with the potential to address unmet medical needs in the oncology space. The fundraising effort is being managed through a share purchase plan, allowing existing shareholders to participate in the company's growth while maintaining a stable investor base. This strategic move positions Prescient Therapeutics to further develop its proprietary therapies and potentially expand its clinical trial programs in the coming years. The company's focus on immune-based therapies aligns with broader trends in cancer research, where immunotherapies are increasingly recognised as a promising avenue for treatment. With the successful completion of these clinical trials, Prescient Therapeutics aims to establish itself as a key player in the rapidly evolving field of cancer therapeutics. The company's progress reflects the growing importance of biotechnology innovation in addressing complex health challenges, particularly in the treatment of cancer. The $8 million capital raise is a significant step in Prescient's journey to bring its groundbreaking therapies to patients who could benefit from these advanced treatments.

YouTube video by Making The Deal

Regulation Crypto Assets offers two exemptions to lure offshore projects back, but CLARITY Act vote looms as the bigger prize

Toronto, Ontario--(Newsfile Corp. - July 14, 2026) - Blockmate Ventures Inc. (TSXV: MATE) (OTCQB: MATEF) (FSE: 8MH) ("Blockmate" or the "Company"), a venture builder focused on AI, Bitcoin and digital infrastructure, is pleased to announce the successful closing of its previously announced non-brokered private placement for gross proceeds of $1.0 million (the "Offering"), exceeding the Company's original financing target of $750,000. Approximately 29% of the Offering was subscribed by directors...

MicroStrategy has raised $467 million by selling common stock and built its cash reserves to $3 billion, while holding its Bitcoin position steady at 843,775 coins. The company has now skipped Bitcoin purchases for three consecutive weeks, instead prioritizing liquid capital reserves.

Precious metals developer Barton Gold, valued at approximately $210 million, has launched a capital raising initiative to secure $25.5 million from equity investors. The company, which owns the only gold mill operating in the central Gawler Craton region of South Australia, is seeking fresh funding to support its ongoing operations and development activities in the gold sector. According to a term sheet circulated to fund managers, Barton Gold has engaged stockbrokers Canaccord Genuity and MST Financial to manage the placement of new shares. The shares are being offered at a price of 85 cents each, representing a 3.4 per cent discount to the company’s most recent closing price and a 7.3 per cent discount to the five-day volume-weighted average price. The discount is intended to attract institutional and sophisticated investors in a competitive capital markets environment. The capital raising comes as the company continues to position itself as a key player in South Australia’s gold production landscape, particularly given its strategic ownership of the only operational gold mill in the central Gawler Craton. The funds raised are expected to provide additional financial flexibility, potentially supporting expansion, exploration, and operational efficiency improvements. The transaction is being closely watched within mining and investment banking circles, as Barton Gold’s relatively modest market capitalisation and unique asset base make it an interesting case within the Australian precious metals sector. The involvement of Canaccord Genuity and MST Financial underscores the institutional nature of the placement and signals confidence in the company’s longer-term prospects despite the discounted issue price.

Challenger Gold, currently suspended from trading, is undergoing significant corporate changes behind the scenes. Its brokers are preparing a major capital raising of $80 million, aimed at strengthening the company’s financial position. Alongside this, there is a substantial reshuffle of both the board and management. Seasoned gold industry executive Peter Marrone is set to become the new chairman and will contribute a significant portion of the proposed funds. The company, which currently has a market capitalisation of $292 million, is positioning itself for a potential turnaround under Marrone's leadership. These moves signal a renewed focus on stabilising the business and enhancing investor confidence, with the capital raising and executive changes intended to lay the foundation for future growth and operational improvements in the gold sector.

YouTube video by Property Profits Real Estate Podcast by Dave Dubeau

In a world where capital is abundant yet increasingly selective, the real differentiator is no longer access—but strategy. Companies that secure funding today aren’t just well-funded—they’re well-advi...